BioVie, Inc. (BIVI) financial statements (2021 and earlier)

Company profile

Business Address 2120 COLORADO AVE.
LOS ANGELES, CA 90404
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12130000
Cash and cash equivalents12130000
Other current assets000111
Total current assets:12130111
Noncurrent Assets
Intangible assets, net (including goodwill)222222
Goodwill000000
Intangible assets, net (excluding goodwill)111111
Total noncurrent assets:222222
TOTAL ASSETS:13152223
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities001111
Accounts payable001111
Due to related parties   00 
Other undisclosed current liabilities  223311
Total current liabilities:00245411
Noncurrent Liabilities
Long-term debt and lease obligation000   
Long-term debt, excluding current maturities000   
Total noncurrent liabilities:000   
Total liabilities:00245411
Stockholders' equity
Stockholders' equity attributable to parent1315(21)(2)(2)(9)
Common stock000000
Additional paid in capital10310220201919
Accumulated deficit(90)(87)(41)(22)(22)(28)
Total stockholders' equity:1315(21)(2)(2)(9)
TOTAL LIABILITIES AND EQUITY:13152223

Income statement (P&L) ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
Gain on disposition of assets for financial service operations 8 070
Gross profit: 8(8)070
Operating expenses(3)(0)(1)(1)(1)(1)
Other undisclosed operating income (loss) (8)8(0)(7)(0)
Operating loss:(3)(0)(1)(1)(1)(1)
Interest and debt expense(0)(1)(1)(0)(0)(3)
Loss before gain (loss) on sale of properties:(3)(1)(2)(1)(1)(4)
Other undisclosed net income (loss) 8(17)070
Net income (loss):(3)7(19)(0)7(4)
Other undisclosed net income attributable to parent0     
Net income (loss) available to common stockholders, diluted:(3)7(19)(0)7(4)

Comprehensive Income ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
Net income (loss):(3)7(19)(0)7(4)
Comprehensive income (loss), net of tax, attributable to parent:(3)7(19)(0)7(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: